Anzeige
Mehr »
Login
Donnerstag, 05.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Edison Investment Research-Archiv vom 20.02.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
20.02.Basilea Pharmaceutica - From strength to strength552FY23 was another strong year for Basilea, marked by successive guidance beats and meaningful progress in fortifying its product pipeline. Revenues of CHF157.6m were ahead of guidance, driven by c 23%...
► Artikel lesen
20.02.Wilmington - Focus on governance, risk and compliance342With November's purchase of Astutis, January's sale of MiExact and the proposed Healthcare business disposal, Wilmington is now firmly focused on opportunities within the large global governance, risk...
► Artikel lesen
20.02.Pan African Resources - A happy valentine296Pan African Resources' (PAF's) H124 results were released on 14 February, with earnings (and headline earnings) within 1.5% of our forecast and normalised headline earnings within 1.2% of our forecast...
► Artikel lesen
20.02.Dentsu Group - Return to organic growth forecast for FY24398Dentsu's FY23 net revenue was a touch above guidance at Q3, with a better-than-expected operating margin reflecting a good Q4 in Japan, further boosted by a short delay in an IT project pushed out to...
► Artikel lesen
20.02.Recce Pharmaceuticals - Supportive advancements on the pipeline274Recce Pharmaceuticals has announced several positive developments in recent weeks relating to its therapeutic programmes, particularly for lead anti-infective candidate RECCE® 327 (R327). It entered...
► Artikel lesen
20.02.Ultimovacs - Another ODD boosts the off-the-shelf, universal UV1366Ultimovacs has been granted Orphan Drug designation (ODD) from the European Medicines Agency (EMA) for UV1 in mesothelioma, marking another step forward for the clinical development of its lead universal...
► Artikel lesen